Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | MPL | P40238 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 12/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.41 |
| ▸ | DRD2 | P14416 | 12/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL472461 | 0.85 | ALOX5AP (0.38) | DRD3KCNH2DRD2ALOX5APFEN1 | |
| SCHEMBL472357 | 0.82 | MPL (0.41) | HSD11B1MPLALOX5APFEN1CYP11B1 | |
| SCHEMBL472583 | 0.81 | MPL (0.39) | HSD11B1MPLALOX5APFEN1CYP11B1 | |
| SCHEMBL13393503 | 0.81 | IMPDH2 (0.38) | DRD3KCNH2DRD2 | |
| SCHEMBL472449 | 0.78 | NMUR2 (0.39) | DRD3KCNH2DRD2ALOX5APFEN1 | |
| SCHEMBL31306329 | 0.78 | KIT (0.38) | ALOX5APFEN1 | |
| SCHEMBL13380090 | 0.76 | LMNA (0.40) | DRD3CHRM3CYP1A2 | |
| SCHEMBL472518 | 0.76 | IMPDH2 (0.47) | DRD3KCNH2DRD2CHRM1CHRM3 | |
| SCHEMBL472420 | 0.74 | IMPDH2 (0.34) | MPLDRD3KCNH2DRD2CHRM1 | |
| SCHEMBL1855319 | 0.74 | NOTUM (0.51) | DRD3KCNH2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2412372-A1 | 2-Aminooxazole derivatives for use as TRPV1 antagonists for treating i.a. pain, inflammation, neurodegenerative diseases or gastrointestinal diseases | Abbott Laboratories (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7998993-B2 | TRPV1 antagonists | ABBOTT LABORATORIES (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2220059-B1 | 2-AMINOOXAZOLE DERIVATIVES AS TRPVL ANTAGONISTS USEFUL FOR TREATING PAIN | ABBOTT LAB (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20090124666-A1 | TRPV1 ANTAGONISTS | ABBOTT LABORATORIES (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124666-A1 | TRPV1 ANTAGONISTS | TRPV1, TRPV2, TRPV3 | HSD11B1 3256/4885MPL 4565/4885DRD3 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.